Details of the Drug Combination

General Information of Drug Combination (ID: DC9PAZM)

Drug Combination Name
MK-3207 Primaquine
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs MK-3207   DM6OLGC Primaquine   DMWQ16I
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 3.926
Bliss Independence Score: 6.58
Loewe Additivity Score: 2.376
LHighest Single Agent (HSA) Score: 6.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-3207
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 2 [2]
MK-3207 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcitonin gene-related peptide receptor (CGRPR) TTY6O0Q CALRL_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Indication(s) of Primaquine
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [3]
Primaquine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Deoxyribonucleic acid (Malaria DNA) TT698WO NOUNIPROTAC . [5]
------------------------------------------------------------------------------------
Primaquine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Primaquine Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [8]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Increases Expression [9]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [9]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [9]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Activity [10]
Hemoglobin subunit gamma-2 (HBG2) OT4J48JJ HBG2_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008316.
4 Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
5 Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
6 Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
7 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
8 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
9 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
10 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
11 Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009 Nov 15;241(1):14-22. doi: 10.1016/j.taap.2009.07.012. Epub 2009 Jul 17.